Serum protein N-glycosylation in paediatric non-alcoholic fatty liver disease

Summary Objective We have previously shown the potential of glycomics to distinguish patients with steatosis from patients with non‐alcoholic steatohepatitis (NASH) in an adult population. The pattern of disease in paediatric patients is distinct from adults. The objective of this study was to chara...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric obesity 2012-04, Vol.7 (2), p.165-173
Main Authors: Blomme, B., Fitzpatrick, E., Quaglia, A., De Bruyne, R., Dhawan, A., Van Vlierberghe, H.
Format: Article
Language:English
Subjects:
Adolescent
Biomarkers - blood
Biopsy
Blood Proteins - metabolism
Child
Cohort Studies
Diagnosis, Differential
Fatty Liver - diagnosis
Fatty Liver - metabolism
Fatty Liver - pathology
Female
glycomics
Glycomics - methods
Glycosylation
Humans
immunoglobulin G
Immunoglobulin G - blood
Liver - metabolism
Liver - pathology
liver steatosis
Male
Non-alcoholic Fatty Liver Disease
protein glycosylation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Objective We have previously shown the potential of glycomics to distinguish patients with steatosis from patients with non‐alcoholic steatohepatitis (NASH) in an adult population. The pattern of disease in paediatric patients is distinct from adults. The objective of this study was to characterize the N ‐glycomic profile of children with varying degrees of non‐alcoholic fatty liver disease (NAFLD) and identify potential biomarker profiles of disease. Methods Serum protein N‐glycosylation patterns of 51 paediatric NAFLD patients were assessed with deoxyribonucleic acid sequencer‐assisted fluorophore‐assisted capillary electrophoresis and compared with histology. Results Peak 1 (NGA2F) is the most significantly elevated N‐glycan in paediatric NASH patients with peak 5 (NA2) demonstrating the largest decrease. The logarithmically transformed ratio of peak 1 to peak 5 was −0.85 (standard deviation [SD] 0.22) in patients with steatosis and borderline NASH and −0.73 (SD 0.12) in NASH (P = 0.02). The biomarker correlated well with the amount of lobular inflammation with a consistent increase of marker score in ascending stage of lobular inflammation. There was also a trend in differentiating patients with significant fibrosis ≥F2; −0.74 (SD 0.13) from patients with no/minimal fibrosis
ISSN:2047-6302
2047-6310
DOI:10.1111/j.2047-6310.2011.00024.x